Loading...
Loading...
Needham has raised the price target on Cubist Pharmaceuticals
CBST from $27 to $33 and following the company's settlement with Teva
TEVA. Buy rating maintained.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: Price TargetAnalyst RatingsBiotechnologycubist pharmaceuticalsHealth CareNeedhamPharmaceuticalsTEVA PHARMACEUTICALS
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
